Pharmacotherapy of Alzheimer Disease
نویسندگان
چکیده
منابع مشابه
A Review of Pharmacotherapy for Coronavirus Disease 2019 (COVID-19)
The epidemic of COVID-19 and its associated acute respiratory syndrome has posed an unprecedented challenge in identifying effective drugs to prevent and treat it. Due to the high prevalence of this disease and the high number of people at risk, medical staff needs accurate evidence regarding effective drug treatments for this infection. There is currently no effective treatment for COVID-19. B...
متن کاملP115: A Novel High Tech Approach to Monitor the Pharmacotherapy of Alzheimer; a Narrative Review
Alzheimer's disease (AD) is multisystem and multifactor disease with a long no-symptom stage. We propose that a more effective approach to use fMRI as a still emerging, repeatable, non- invasive neuroimaging tools that can be very useful for evaluating, diagnosis, treatment and drugs- development. We studied 30 articles which published between 2008-2017 that included the effects of different bi...
متن کاملSubdural Pharmacotherapy Device Adapted to the Treatment of Alzheimer ’ s Disease
Citation: Nandor Ludvig. “Subdural Pharmacotherapy Device Adapted to the Treatment of Alzheimer’s Disease”. EC Neurology 1.S1 (2015): S1-S5. According to the World Alzheimer Report 2014 [1], dementias, mostly Alzheimer’s disease (AD), affect about 44 million people worldwide with the global annual costs exceeding $600 billion. Yet, none of the approved drugs for AD is effective to even signific...
متن کاملUzbay Alzheimer disease and neuroplasticity : New approaches and new targets in pharmacotherapy
INTRODUCTION Alzheimer’s disease (AD) was first identified in 1906 by Alois Alzheimer, a German psychiatrist and neuropathologist (Figure 1). AD is the major cause of dementia in the middle-to old-aged individuals and is a chronic and progressive disorder with an average disease progression of approximately ten years (1). Currently, almost 35 million people worldwide are suffering from AD. Acco...
متن کاملP 133: Neuroinflammation in Alzheimer ’s Disease
Alzheimer’s disease (AD) is a neurodegenerative disorder and the most common form of dementia. Almost 47 million people suffer from dementia worldwide. AD accounts for approximately 60%–80% of all dementia cases. Three major pathologies characterize the disease: senile plaques, neurofibrillary tangles and inflammation. We review the literature on events contributing to the inflammat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Canadian Journal of Psychiatry
سال: 2007
ISSN: 0706-7437,1497-0015
DOI: 10.1177/070674370705201003